A new research perspective titled "Targeting the multifaceted BRAF in cancer: New directions" has been published in Oncotarget. In cancer patients, BRAF-targeting precision therapeutics are effective ...

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

Resistance to targeted therapies poses a significant challenge in advanced melanoma with BRAF mutations. Even with a BRAF + MEK inhibitor combination, about 70% of patients experience disease ...

Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy in advanced stages. Chemotherapy has not demonstrated its efficacy in MM and current treatment for tumors carrying the ...

Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor. Outcomes of ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...